From Placebo Journal Blog - Medical Humoour with a Purpose - March 3
The most common strain of flu in the United States this year is H1N1 and CDC researchers said 98 percent of all flu samples from that strain were resistant to Roche AG's Tamiflu. Call me crazy but that's a pretty bad success rate. I am not saying this is a bad drug and even last year the same strain was only 19 percent resistant. What I look forward to seeing is the what the drug companies do for advertising over the next few weeks. Winter sure isn't over in Maine as we are cooped up with mounds of snow around us. What I am seeing is a lot more URIs and I wonder if Relenza (the GSK product that rivals Tamiflu) is going to get a little cocky with this news. I also wonder if the Roche will show some ethics and pull back on its advertising? Their website is actually very informative at http://www.tamiflu.com/ but they haven't mentioned this new information yet. Or maybe they are both broke and don't care so much anymore? More to come. Maybe
BTA Price at posting:
$1.38 Sentiment: LT Buy Disclosure: Held
